Diarrhea Treatment Pipeline: Comprehensive 2025 Analysis

DelveInsight's "Diarrhea Pipeline Insight 2025" analysis delivers extensive perspectives on 25+ organizations and 25+ investigational therapies within the Diarrhea pipeline environment. It encompasses Diarrhea Pipeline drug candidate profiles, spanning clinical and nonclinical development stages. The analysis additionally features Diarrhea Pipeline Treatment evaluation by product classification, developmental phase, administration route, and molecular category. It further spotlights the dormant pipeline assets in this therapeutic domain.

Interested in the most recent developments in the Diarrhea Pipeline? Access here to discover the treatments and studies generating attention @ Diarrhea Pipeline Outlook Report

Essential Highlights from the Diarrhea Pipeline Analysis

On 22 September 2025, Immuron Ltd. initiated an investigation to evaluate whether Travelan® safeguards healthy adult participants from moderate-to-severe diarrhea following exposure to Enterotoxigenic Escherichia coli (ETEC) strain H10407.

DelveInsight's Diarrhea Pipeline analysis reveals a dynamic landscape with 25+ active organizations engaged in advancing 25+ pipeline candidates for Diarrhea management.

Prominent Diarrhea pharmaceutical developers include RedHill Biopharma Limited, Puma Biotechnology, Inc., Hunazine Biotech, Vedanta Biosciences, Inc., Crinetics Pharmaceuticals Inc., MGB Biopharma Limited, Daewoong Pharmaceutical Co. LTD., Eveliqure Biotechnologies GmbH, Inmunova S.A., GlaxoSmithKline among others.

Promising Diarrhea Treatment Assets include Carbowhite, Nitazoxanide, OPT-80, Racecadotril plus ORS, Rifaximin, Xifaxan®, Elsiglutide among others.

Seeking to identify which organizations are driving innovation in Diarrhea therapeutics? Access the complete pipeline perspectives @ Diarrhea Clinical Trials Assessment

The Diarrhea Pipeline Analysis offers disease background, pipeline landscape and therapeutic evaluation of the principal pipeline candidates in this field. The Diarrhea Pipeline Analysis additionally emphasizes the unaddressed medical needs concerning Diarrhea.

Understanding Diarrhea

Diarrhea is characterized by experiencing three or more loose or liquid bowel movements in a single day, or occurring more frequently than typical patterns. Diarrheal episodes are commonly triggered by gastrointestinal infection (gastroenteritis) and resolve independently within several days. Nevertheless, numerous additional etiologies of diarrhea exist. Most diarrheal cases are mild in severity, though it may also present as severe requiring hospital admission. Diarrhea represents the elevation of water content in fecal matter due to disruption in the normal physiologic mechanisms of the small and large bowel responsible for absorbing various electrolytes, other compounds, and subsequently water. Acute diarrhea is characterized as the sudden onset of three or more loose or watery bowel movements daily persisting for 14 days or less.

Diarrhea Investigational Drug Profiles

VE303: Vedanta Biosciences, Inc. VE303 represents an orally administered, rationally-designed, defined bacterial consortium under development for high-risk Clostridioides difficile (CDI) infection. VE303 comprises 8 clonal human commensal bacterial strains specifically selected for their capacity to confer colonization resistance against C. difficile and produced under CGMP standards. Presently, this agent is undergoing Phase III clinical evaluation for diarrhea disease management.

RHB-102: RedHill Biopharma Limited RHB-102 is a proprietary, bimodal release, once-daily oral formulation of the antiemetic agent ondansetron, addressing multiple gastrointestinal conditions. RHB-102 24 mg is designed to deliver patients with alleviation from nausea and vomiting manifestations throughout a complete 24-hour duration with a single oral dose. Presently, this therapeutic is undergoing Phase II clinical investigation for diarrhea disease treatment.

VR-AD-1005: Hunazine Biotech VR-AD-1005, a novel antidiarrheal investigational agent for the innovative management of severe cholera-associated diarrhea. VR-AD-1005 is designed to function by diminishing the volume of liquid stool generated by the intestinal tract when afflicted by the diarrheal pathogen. This agent operates within the intestinal lumen without impacting motility and does not trigger constipation. Presently, this therapeutic is in Phase II clinical development for severe cholera-associated diarrhea treatment.

ShigETEC: Eveliqure Biotechnologies GmbH ShigETEC represents an orally administered vaccine that elicits comprehensive protection against Shigella in a serotype-independent manner and concurrently against ETEC, two principal pathogens causing diarrhoeal conditions. According to preclinical evidence produced by Eveliqure throughout the previous 5 years, it demonstrates potential to become a best-in-class diarrhoea vaccine addressing both travelers and populations in low- and middle-income regions. Presently, this agent is undergoing Phase I clinical evaluation for diarrhea disease management.

For those monitoring active Diarrhea Clinical investigations, this communication is essential reading. Access to view the advances @ Diarrhea Treatment Drugs

The Diarrhea Pipeline Analysis Delivers Perspectives on:

The analysis offers comprehensive insights regarding organizations advancing treatments for Diarrhea management with aggregate therapeutic candidates developed by individual companies for this indication.

It evaluates various therapeutic assets categorized into initial-stage, intermediate-stage, and advanced-stage development for Diarrhea Treatment.

Diarrhea pharmaceutical developers engaged in targeted therapeutic advancement with corresponding active and inactive (dormant or terminated) programs.

Diarrhea therapeutics under investigation are classified by development phase, administration route, target receptor, monotherapy or combination approaches, distinct mechanisms of action, and molecular classification.

Comprehensive examination of partnerships (inter-company collaborations and company-academic institution partnerships), licensing agreements and funding arrangements for future progression of the Diarrhea market.

Diarrhea Pharmaceutical Developers

RedHill Biopharma Limited, Puma Biotechnology, Inc., Hunazine Biotech, Vedanta Biosciences, Inc., Crinetics Pharmaceuticals Inc., MGB Biopharma Limited, Daewoong Pharmaceutical Co. LTD., Eveliqure Biotechnologies GmbH, Inmunova S.A., GlaxoSmithKline among others.

The Diarrhea Pipeline analysis delivers therapeutic classification of pipeline candidates by Administration Route. Assets have been organized across various administration methods including:

• Oral

• Intravenous

• Subcutaneous

• Parenteral

• Topical

Diarrhea Assets have been categorized across various Molecular classifications including:

• Recombinant fusion proteins

• Small molecule

• Monoclonal antibody

• Peptide

• Polymer

• Gene therapy

From investigational drug candidates to competitive intelligence, the Diarrhea Pipeline Analysis encompasses comprehensive information – access it now @ Diarrhea Market Drivers and Barriers, and Future Perspectives

Parameters of the Diarrhea Pipeline Analysis

Geographic Coverage: Global

Diarrhea Pharmaceutical Organizations: RedHill Biopharma Limited, Puma Biotechnology, Inc., Hunazine Biotech, Vedanta Biosciences, Inc., Crinetics Pharmaceuticals Inc., MGB Biopharma Limited, Daewoong Pharmaceutical Co. LTD., Eveliqure Biotechnologies GmbH, Inmunova S.A., GlaxoSmithKline among others.

Diarrhea Treatment Assets: Carbowhite, Nitazoxanide, OPT-80, Racecadotril plus ORS, Rifaximin, Xifaxan®, Elsiglutide among others.

Diarrhea Treatment Evaluation by Product Classification: Monotherapy, Combination therapy, Monotherapy/Combination therapy

Diarrhea Treatment Evaluation by Clinical Phases: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Maintain leadership in Healthcare Research – identify what's emerging for the Diarrhea Treatment landscape in this comprehensive examination @ Diarrhea Emerging Drugs and Major Players

Report Contents

• Introduction

• Executive Summary

• Diarrhea: Disease Overview

• Pipeline Treatment Options

• Therapeutic Evaluation

• Diarrhea – DelveInsight's Strategic Perspective

• Advanced Stage Assets (Phase III)

  • VE303: Vedanta Biosciences, Inc.

  • Drug profiles in the comprehensive analysis…..

• Intermediate Stage Assets (Phase II)

  • VR-AD-1005: Hunazine Biotech

  • Drug profiles in the comprehensive analysis…..

• Initial Stage Assets (Phase I)

  • ShigETEC: Eveliqure Biotechnologies GmbH

  • Drug profiles in the comprehensive analysis…..

• Preclinical and Discovery Phase Assets

  • Drug name: Company name

  • Drug profiles in the comprehensive analysis…..

• Discontinued Assets

• Diarrhea Principal Organizations

• Diarrhea Principal Assets

• Diarrhea - Unaddressed Medical Needs

• Diarrhea - Market Growth Catalysts and Obstacles

• Diarrhea - Future Outlook and Summary

• Diarrhea Expert Perspectives

• Diarrhea Principal Organizations

• Supplementary Materials

About Us

DelveInsight operates as a premier healthcare-oriented market research and advisory organization delivering high-caliber market intelligence and strategic analysis to support evidence-based business planning. Supported by a team of seasoned industry specialists and comprehensive expertise in life sciences and healthcare domains, we deliver tailored research solutions and strategic insights to clients worldwide. Partner with us to access premium, precise, and real-time intelligence for maintaining competitive advantage.

Contact Us

Kanishk

kkumar@delveinsight.com